Can a radioactive peptide spot hidden amyloid in the heart?

NCT ID NCT05951816

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This Phase 1 trial is testing a new radioactive tracer called 99mTc-p5+14 to see how it spreads through the body and how much radiation it delivers. The study includes healthy volunteers and people with AL or ATTR systemic amyloidosis, a condition where abnormal protein deposits build up in organs, especially the heart. Researchers want to find out if this tracer can safely and clearly light up amyloid deposits on special scans, potentially offering a better way to detect and monitor the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radioactive tracer called 99mTc-p5+14, designed to bind to amyloid deposits in the body
What this could lead to
If successful, this tracer could offer a new way to detect and monitor amyloid buildup in organs like the heart, potentially improving diagnosis and treatment planning for people with systemic amyloidosis.
What could go wrong
This is an early Phase 1 study with only 31 participants, so the tracer may not prove safe or effective enough for wider use. The main focus is on radiation exposure and imaging quality, not yet on patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Tennessee Graduate School of Medicine

    RECRUITING

    Knoxville, Tennessee, 37920, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.